What does Allakos, Inc. do?

Jun 22 2025 06:50 PM IST
share
Share Via
Allakos, Inc. is a clinical-stage biotechnology company focused on developing antibodies targeting mast cells and eosinophils. It has a market cap of $29.40 million and reported a net profit loss of $26 million as of March 2025.
Overview:
Allakos, Inc. is a clinical-stage biotechnology company engaged in developing antibodies that selectively target mast cells and eosinophils within the pharmaceuticals industry, categorized as a micro-cap company.

Financial Snapshot:
Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025)
Market-cap: USD 29.40 Million (Micro Cap)

Key Metrics:
P/E: NA (Loss Making)
Industry P/E: NA
Dividend Yield: 97.55%
Debt Equity: -1.00
Return on Equity: -170.81%
Price to Book: 0.53

Contact Details:
Address: 975 Island Dr Ste 201, REDWOOD CITY CA: 94065-5173
Tel: 1 650 5975002
Website: http://www.allakos.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Who are in the management team of Allakos, Inc.?
Jun 22 2025 10:35 PM IST
share
Share Via
How big is Allakos, Inc.?
Jun 22 2025 06:06 PM IST
share
Share Via